Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lenalidomide prolonged-release formulation NEX-20A

A prolonged-release formulation composed of a suspension of the thalidomide analog lenalidomide coated with slow-dissolving nontoxic inorganic oxides, with potential antineoplastic activity. Upon administration via subcutaneous injection, the coating dissolves and lenalidomide is released. Lenalidomide inhibits tumor necrosis factor alpha (TNF-alpha) production, stimulates T lymphocytes, reduces serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibits angiogenesis. Additionally, lenalidomide promotes G1 cell cycle arrest and induces apoptosis in malignant cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:lenalidomide long-acting formulation NEX-20A
Code name:NEX 20A
NEX-20A
NEX20A
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search